[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Regionshospital Nordjylland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":163},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,84,109,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100645127","effect-of-foot-orthoses-on-kneecap-position-in-adults-with-flexible-flatfoot-100645127",false,"NCT07678840","Effect of Foot Orthoses on Kneecap Position in Adults With Flexible Flatfoot","Does Correction of Pronated Foot Posture Alter Patellofemoral Alignment? A Weight-Bearing Cone Beam CT Proof-of-Concept Study in Individuals With Flexible Flatfoot","Inclusion criteria\n\n* Age 18-35 years\n* Pronated foot posture, defined as a Foot Posture Index (FPI) score of ≥ +6, including a calcaneal frontal plane position sub-score of +2. 25,26\n\n  ○ A trained examiner will assess FPI; inclusion is based on the right foot.\n* Flexible flatfoot deformity, defined as restoration of the medial longitudinal arch during lift of the first toe.\n\nExclusion criteria\n\n* Knee pain during standing or at 20° knee flexion\n* Clinical signs of tibiofemoral instability\n* Previous knee or foot surgery\n* History of patellar dislocation\n* Neuromuscular disease\n* Pregnancy\n* Inability to perform full weight bearing during scans","ALL","18 Years","35 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will look at whether correcting a flat foot position with foot orthoses, also called shoe inserts, can change the position of the kneecap during standing.\n\nSome people with flexible flatfoot have a foot position that may affect how the lower leg and knee are aligned. This may influence the way the kneecap sits or tilts in relation to the thigh bone. Foot orthoses are often used for knee and foot problems, but it is not clear whether they directly change kneecap position when a person is standing and bearing weight.\n\nThe study will include adults with flexible flatfoot. Each participant will have low-dose, three-dimensional weight-bearing cone beam CT scans while standing in different foot positions: their natural foot position, with foot orthoses, and with foot orthoses inside a neutral running shoe. Scans will be performed with the knees straight and slightly bent.\n\nThe main hypothesis is that correcting a pronated flat foot position with foot orthoses will reduce sideways tilt and outward shift of the kneecap compared with the participant's natural foot position. The study will also examine whether changes in foot position are accompanied by changes in lower-limb rotation.\n\nThis study does not test whether foot orthoses reduce pain. Instead, it is designed to understand the immediate mechanical effect of foot correction on kneecap position.",[27,28,29],"Patellofemoral Alignment","Patellofemoral Joint","Flatfoot",[29,31,32,33,34,35,36,37,38,39],"Foot pronation","Foot orthoses","Patellofemoral alignment","Patellar tilt","Kneecap position","Lower-limb alignment","Lower-limb rotation","Weight-bearing Imaging","Cone-Beam Computed Tomography","NOT_YET_RECRUITING","2026-06-25",{"date":43,"type":44},"2026-07-01","ACTUAL",{"date":43,"type":21},{"date":47,"type":21},"2026-12-01",{"name":49,"class":50},"Regionshospital Nordjylland","OTHER_GOV",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":4,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":51},"100635174","phase-2-cannabidiol-for-pain-relief-of-patients-with-end-stage-mcrpc-100635174","NCT07549256","Cannabidiol for Pain Relief of Patients With End-stage mCRPC","Efficacy and Safety of Cannabidiol for Pain Relief of Patients With End-stage Metastatic Castration Resistant Prostate Cancer - a Randomised Double-blinded Placebo-controlled Phase II Trial","ProCan","Inclusion Criteria:\n\n* Patients diagnosed with mCRPC as documented by increasing PSA despite optimally attempted treatment, and no other therapeutic options.\n* Treatment-resistance or ineligible to standardized cancer therapy, incl. medical and surgical castration, chemotherapy, and super hormone treatment.\n* Minimum 3 months since radiation therapy, if part of treatment.\n* Perception of pain\n* Daily use of Morphine (ATC: N02AA01) (10mgx2) in relief of pain.\n\nExclusion Criteria:\n\n* Perception of worst pain \\\u003C4.0 on the NRS within the last week prior to baseline visit70. (Inclusion if: three days with highest pain intensity have an average of ≥4.0 and\u002For three days where pain intensity is at least 4.0).\n* Pattern of short duration of response to all previous treatment regimens (\\\u003C6 months) clinically assessed by the investigator.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\>3 (scale 0-5).\n* Change in regular use of conventional pain medication within two weeks prior to baseline visit.\n* A history of substance use disorder.\n* Functional liver insufficiency with an alanine transaminase (ALT) \\>2X ULN and\u002For bilirubin \\>2X ULN assessed by a blood sample taken at screening.\n* Renal failure with an estimated glomerular filtration rate (eGFR) \\\u003C 30mL\u002Fmin\u002F1,73m2 assessed by a blood sample taken at screening.\n* Known heart failure - New York Heart Association III - IV (scale I-IV)71.\n* Known severe chronic obstructive lung disease (Forced Expiratory Volume in the first second (FEV1) \\\u003C50%)72.\n* Use of THC-containing cannabis products measured by a urine sample at screening.\n* Any chronic or acute systemic medical condition that, in the opinion of the investigator, may pose a risk to the safety of the patient or may interfere with compliance or the assessment of efficacy in this trial.\n* Hypersensitivity to the active substance\n* Not capable of giving informed consent.\n* Not capable of understanding, write or read Danish.","MALE",{"count":62,"type":21},58,[64],"PHASE2","The goal of this clinical trial is to evaluate the effects of cannabidiol in patients with end-stage metastatic castration-resistant prostate cancer (mCRPC).\n\nThe primary objective is to determine whether cannabidiol (CBD) treatment can reduce the need for opioids in patients with end-stage mCRPC.\n\nAdditionally, the study will assess a range of clinical endpoints in patients with end-stage mCRPC, including:\n\n1. The efficacy of CBD treatment in alleviating pain\n2. The efficacy of CBD treatment in reducing the need for non-opioid medications and concomitant therapies\n3. The impact of CBD treatment on physical activity and quality of life\n4. The anti-inflammatory and potential anti-tumor properties of CBD\n5. The safety of CBD treatment\n\nPatients from Department of Urology, Aalborg University Hospital will be included. Participants will be treated with either CBD (200 mg) or placebo (0 mg) three times daily for nine weeks. At baseline, halfway and end of trial, participants will use an activity tracker and complete questionnaires regarding pain and quality of life and provide blood samples to measure inflammation and tumor activity. Also, they will complete a daily dairy regarding the study drug and intake of pain medication. Adverse events will be assessed by Common Terminology Criteria for Adverse Events.",[67],"Metastatic Castration Resistant Prostate Cancer (mCRPC)",[69,70,71,72,73,74,75],"Cannabidiol","CBD","Prostate cancer","Adjuvant palliative therapy","Cannabis","Metastatic castration resistant prostate cancer","mCRPC","2026-04-17",{"date":78,"type":44},"2026-04-24",{"date":80,"type":21},"2026-06-01",{"date":82,"type":21},"2029-01",{"name":49,"class":50},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":51},"100629583","evaluating-the-efficacy-of-suture-mesh-vs-planar-mesh-in-ventral-hernia-treatment-100629583","NCT07476560","Evaluating the Efficacy of Suture Mesh vs. Planar Mesh in Ventral Hernia Treatment","Mesh Matters: Evaluating the Efficacy of Suture Mesh vs. Planar Mesh in Ventral Hernia Treatment - a Randomized, Blinded Multicenter Study","MeMa","Inclusion Criteria:\n\n* Ventral hernia (maximum size 3 × 3 cm) measured with Ultrasound or CT.\n* Participants must be eligible for surgical repair using either mesh-suture or planar mesh\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Acute (emergent) operation.\n* Pregnancy.\n* Women with plans for future pregnancies.\n* Withdrawal of informed consent during admission.",{"count":93,"type":21},280,[24],"The goal of this clinical trial is to investigate whether mesh-suture affects wound complication rates, patient-reported quality of life, and operation time in adult patients undergoing surgery for small ventral hernias.\n\nThe main questions it aims to answer are:\n\nDoes mesh-suture reduce wound complication rates compared to planar mesh? Does mesh-suture improve patient-reported quality of life(QoL) and affect operation time compared to planar mesh?\n\nComparison group:\n\nResearchers will compare standard treatment with planar mesh to the interventional treatment with mesh-suture to see whether mesh-suture leads to fewer complications, better quality of life, and shorter operation time.\n\nParticipants will:\n\nBe randomized to receive either planar mesh or mesh-suture during hernia repair surgery.\n\nUndergo standardized preoperative assessment, including baseline data and QoL scoring.\n\nAttend a postoperative visit on day 7-13 for wound inspection and ultrasound. Complete QoL assessments at 90 days (telephone follow-up). Have operation time recorded and medical records reviewed for readmissions within 90 days.",[97,98,99],"Abdominal Wall Hernia","Umbilical Hernia Repair","Epigastric Hernia Repair","RECRUITING","2026-03-12",{"date":103,"type":44},"2026-03-17",{"date":105,"type":44},"2026-01-05",{"date":107,"type":21},"2032-12-31",{"name":49,"class":50},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":51},"100434792","biomarkers-as-predictors-of-chronic-heart-failure-in-patients-with-type-2-diabetes-100434792","NCT04941794","Biomarkers as Predictors of Chronic Heart Failure in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* Type 2 diabetes\n* age \\> 50 years\n\nExclusion Criteria:\n\n* History of acute or chronic heart failure\n* History of ischemic heart disease",true,"50 Years",{"count":118,"type":21},500,"OBSERVATIONAL","A cohort study on patients with type 2 diabetes to investigate possible biomarkers as predictors of chronic heart failure.",[122,123],"Type 2 Diabetes","Chronic Heart Failure","2026-03-06",{"date":126,"type":44},"2026-03-10",{"date":128,"type":44},"2021-07-01",{"date":130,"type":21},"2027-07",{"name":49,"class":50},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},"100570053","phase-2-newborn-jaundice---an-investigation-of-different-approaches-to-light-therapy-100570053","NCT06702241","Newborn Jaundice - An Investigation of Different Approaches to Light Therapy","Neonatal Hyperbilirubinemia - Phototherapeutic Treatment Strategies","Inclusion Criteria:\n\n* Hyperbilirubinemia with a total serum bilirubin level above the limit of necessary treatment according to the Danish Pediatric Society's guidelines\n* Birth weight \\>1800g\n* Gestational age \\>33+0\n\nExclusion Criteria:\n\n* Hyperbilirubinemia within the first 24 hours of life\n* Rapidly increasing serum levels of bilirubnemia indicating pathology or hemolysis","1 Day","14 Days",{"count":142,"type":21},116,[64,144],"PHASE3","Background Neonatal jaundice affects about 60% of full-term newborns in their first week. If untreated, it can lead to permanent brain damage. In Denmark, 2-5% of newborns require phototherapy, the standard treatment. The maximum beneficial irradiance limit for phototherapy remains unclear. Furthermore, studies suggest that cycled phototherapy is as effective as continuous treatment.\n\nThis study aims to investigate the efficacy of elevating the irradiance of intensive phototherapy treatment regimens. This is to evaluate the dose-response relationship. Furthermore, the study aims to compare intermittent phototherapy to continuous phototherapy.\n\nMethods:\n\nIn a clinical randomized multicenter trial 116 newborns with non-hemolytic hyperbilirubinemia, gestational age \\>33+0, weight \\>1800g and no other significant neonatal diagnose will be randomized. All infants will receive 12 hours double therapy with a biliblanket and overhead light providing an intensity of either 40-, 55- or 70 µW\u002Fcm2\u002Fnm. Three groups will be treated with continuous phototherapy while a fourth group will receive intermittent phototherapy of 1,5 hours cycled intervals with an intensity of 70 µW\u002Fcm2\u002Fnm.\n\nParental experiences during treatment will be examined through a survey post treatment.\n\nThe study has been approved by the Regional Research Ethics Committee.\n\nPerspectives:\n\nUnderstanding the dose-response relationship of phototherapy will give an insight in the most effective way of treating neonatal jaundice. Intermittent therapy, if proven non-inferior, could facilitate more intimacy in the parent-infant relationship as well as benefits in initiating breastfeeding",[147],"Neonatal Hyperbilirubinemia",[149,150,151,152,153],"Cycled phototherapy","high irradiance phototherapy","Neonatal jaundice","Newborn jaundice","neonatal hyperbilirubinemia","2025-11-17",{"date":156,"type":44},"2025-11-20",{"date":158,"type":44},"2025-01-14",{"date":160,"type":21},"2029-11-01",{"name":49,"class":50},2,""]